BioRestorative Therapies Inc Asset Resilience Ratio
BioRestorative Therapies Inc asset resilience ratio. BioRestorative Therapies Inc (BRTX) has an Asset Resilience Ratio of 10.33% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BioRestorative Therapies Inc (BRTX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioRestorative Therapies Inc (2021–2025)
Asset resilience ratio of BioRestorative Therapies Inc from 2021 to 2025. This chart shows how BioRestorative Therapies Inc's Asset Resilience Ratio has changed over time. Read BioRestorative Therapies Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BioRestorative Therapies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BioRestorative Therapies Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $479.35K | 10.33% |
| Total Liquid Assets | $479.35K | 10.33% |
Asset Resilience Insights
- Moderate Liquidity: BioRestorative Therapies Inc has 10.33% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
BioRestorative Therapies Inc Industry Peers by Asset Resilience Ratio
Compare BioRestorative Therapies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
BioRestorative Therapies Inc Asset Resilience Ratio by Year (2021–2025)
BioRestorative Therapies Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for BioRestorative Therapies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.34% | $1.44 Million | $4.08 Million | -47.60pp |
| 2024-12-31 | 82.94% | $10.18 Million | $12.28 Million | +2.21pp |
| 2023-12-31 | 80.73% | $10.18 Million | $12.61 Million | +1.41pp |
| 2022-12-31 | 79.32% | $13.04 Million | $16.43 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $22.45 Million | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more